Financial Performance - Net profit attributable to shareholders decreased by 24.04% to CNY 14,673,681.53 for Q1 2024, down from CNY 19,317,763.05 in Q1 2023[10] - Operating revenue fell by 19.04% to CNY 92,158,215.06 in Q1 2024, compared to CNY 113,826,553.83 in the same period last year[10] - Total operating revenue for Q1 2024 was ¥92,158,215.06, a decrease of 19.1% compared to ¥113,826,553.83 in Q1 2023[38] - Net profit for Q1 2024 was ¥14,673,681.53, representing a decline of 23.5% from ¥19,317,763.05 in Q1 2023[39] - Basic and diluted earnings per share for Q1 2024 were both ¥0.30, compared to ¥0.41 in Q1 2023, reflecting a decrease of 26.8%[40] - Total operating costs for Q1 2024 were ¥74,871,309.12, down 20% from ¥93,581,956.81 in Q1 2023[38] - Research and development expenses in Q1 2024 were ¥3,732,394.90, down 21.7% from ¥4,767,197.60 in Q1 2023[38] - Investment income for Q1 2024 was ¥379,280.29, a decrease of 37.3% from ¥605,723.49 in Q1 2023[39] - Tax expenses for Q1 2024 were ¥2,673,200.53, down 17.2% from ¥3,229,003.40 in Q1 2023[39] - The company achieved a gross profit margin of 18.8% in Q1 2024, compared to 17.6% in Q1 2023[38] Cash Flow and Liquidity - The net cash flow from operating activities surged by 2,616.46% to CNY 15,376,630.73, compared to a negative cash flow of CNY 611,042.28 in Q1 2023[10] - Cash inflow from operating activities totaled CNY 91,024,902.21 in Q1 2024, compared to CNY 93,150,584.41 in Q1 2023, reflecting a slight decrease of about 2.3%[43] - Cash outflow from operating activities was CNY 75,648,271.48 in Q1 2024, a decrease from CNY 93,761,626.69 in Q1 2023, indicating a reduction of approximately 19.3%[43] - The ending cash and cash equivalents balance for Q1 2024 was CNY 101,749,695.63, significantly higher than CNY 38,540,430.42 at the end of Q1 2023[44] - Cash inflow from sales of goods and services was CNY 83,611,996.41 in Q1 2024, down from CNY 90,552,198.64 in Q1 2023, a decrease of approximately 7.5%[43] - Cash received from investment redemption decreased by 75.48% to CNY 35,000,000[14] - Cash outflow from investment activities reached CNY 246,029,196.95 in Q1 2024, compared to CNY 135,258,550.86 in Q1 2023, an increase of approximately 82%[44] - Total cash inflow from investment activities in Q1 2024 was CNY 37,671,961.41, down from CNY 145,082,558.36 in Q1 2023, representing a decrease of about 74%[44] Assets and Liabilities - Total assets increased by 4.27% to CNY 782,225,879.68 as of March 31, 2024, compared to CNY 750,219,591.30 at the end of 2023[10] - The company's total liabilities to assets ratio decreased to 18.07% from 21.75% year-on-year[10] - The total number of unrestricted shares increased from 14,820,300 to 16,820,100, representing 25.98% of the total[19] - The total number of restricted shares increased from 47,579,700 to 47,919,900, representing 74.02% of the total[20] - The total share capital increased from 62,400,000 to 64,740,000 shares[20] - The total assets as of March 31, 2024, amounted to CNY 506,382,273.88, slightly down from CNY 507,484,303.98 at the end of 2023, indicating a decrease of approximately 0.22%[31] - The company's cash and cash equivalents decreased from CNY 310,976,558.02 to CNY 287,055,387.59, representing a decline of about 7.7%[31] - The total liabilities were not explicitly stated, but the company reported a significant increase in trading financial assets from CNY 43,241,999.35 to CNY 74,274,860.56, which is an increase of approximately 71.9%[31] - The company’s long-term equity investments decreased from CNY 4,189,815.52 to CNY 2,382,905.56, a decline of approximately 43.1%[31] - The company’s inventory remained relatively stable, with a slight increase from CNY 62,509,106.71 to CNY 62,839,761.04, reflecting a growth of about 0.53%[31] Shareholder Information - The number of shareholders holding more than 5% of shares includes Li Songnian with 59.87% and Wuxi Crystal Investment with 4.63%[21] - The total equity attributable to shareholders increased to ¥642.90 billion from ¥588.89 billion, representing an increase of approximately 9.2%[37] Other Financial Activities - The company purchased structured deposits worth CNY 60 million to enhance asset preservation and maximize shareholder value[11] - The company reported a significant increase in interest income by 373.85% to CNY 1,128,160.08 due to a substantial increase in bank deposit balances[13] - The company’s other income decreased by 63.07% to CNY 370,100.00, primarily due to a reduction in government subsidies[13] - The company’s contract liabilities decreased by 63.34% to CNY 2,254,490.55, reflecting a shift in sales recognition[12] - The company’s cash received from tax refunds increased by 292.90% to CNY 6,384,537.60, attributed to a higher amount of refundable tax credits[13] - Non-recurring gains and losses totaled CNY 565,988.71, with a net amount after tax of CNY 482,406.50[17] - The company has committed to selling goods worth CNY 15,000,000.00 to related party Wuxi Jingyang Biotechnology Co., Ltd. in 2024, with no transactions recorded as of the report date[26] - The company has established a fund management agreement with its controlling shareholder, Li Songnian, to ensure the fulfillment of financial commitments, with CNY 20,000,000 deposited into a joint account[27] - The company reported that 6.05% of its total assets, valued at CNY 47,323,790.00, are under pledge due to bank acceptance bills[28] - The company has not reported any litigation or arbitration matters during the reporting period, indicating a stable legal standing[25] - The company has not engaged in any external guarantees or loans, maintaining a conservative financial strategy[25]
无锡晶海(836547) - 2024 Q1 - 季度财报